USE OF NAMES AND PUBLICATION. 13.1 Nothing contained in this Agreement shall be construed as granting any right to the Company or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of the Licensor or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of the Licensor; provided, however, that the Licensor acknowledges and agrees that the Company may use the name of the Licensor in various documents used by the Company for capital raising and financing without such prior written consent where the use of such names may be required by law. The Company agrees to promptly provide the Licensor with a copy of any documents used by the Company, which contain the name of the Licensor. The Licensor may act as a consultant and scientific advisor to the Company with respect to the licenses granted to the Company hereunder, subject to the policies, if any, of the Licensor.
13.2 Nothing herein shall be deemed to establish a relationship of principal and agent between the Licensor and the Company, nor any of their agents or employees for any purpose whatsoever. This Agreement shall not be construed as creating a partnership between the Licensor and the Company, or as creating any other form of legal association or arrangement which would impose liability upon one party for the act or failure to act of the other party.
13.3 In the event that the Licensor desires to publish or disclose, by written, oral or other presentation, Know-how, Patent Rights, or any material information related thereto then the Licensor shall notify the Company in writing by facsimile where confirmed by the receiving party, and/or by certified or registered mail (return receipt requested) of its intention at least sixty (60) days prior to any speech, lecture or other oral presentation and at least sixty (60) days before any written or other publication or disclosure. The Licensor shall include with such notice a description of any proposed oral presentation or, in any proposed written or other disclosure, a current draft of such proposed disclosure or abstract. The Company may request that the Licensor, no later than thirty (30) days following the receipt of such notice, delay such presentation, publication or disclosure in order to enable the Company to file, or have filed on their behalf, a patent application, copyright or other appropriate form of intellectual property...
USE OF NAMES AND PUBLICATION. 14.1 Nothing contained in this Agreement shall be construed as granting any right to the Company or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of Ovamed or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of Ovamed; provided, however, that Ovamed acknowledges and agrees that the Company may use the name of Ovamed in various documents used by the Company for capital raising and financing without such prior written consent and where the use of such names may be required by law.
14.2 Nothing herein shall be deemed to establish a relationship of principal and agent between Ovamed and the Company, nor any of their agents or employees for any purpose whatsoever.
14.3 In the event that Ovamed desires to publish or disclose, by written, oral or other presentation, Patent Rights, Know-how, or any material information related thereto then Ovamed shall notify the Company and in writing by facsimile where confirmed by the receiving party, and/or by certified or registered mail (return receipt requested) of their intention at least [*******] days prior to any speech, lecture or other oral presentation and at least [*******] days before any written or other publication or disclosure. Ovamed shall include with such notice a description of any proposed oral presentation or, in any proposed written or other disclosure, a current draft of such proposed disclosure or abstract. The Company may request that Ovamed, no later than [*******] days following the receipt of such notice, delay such presentation, publication or disclosure for up to an additional [*******] days in order to enable the Company
USE OF NAMES AND PUBLICATION. 14 ARTICLE 14 -
USE OF NAMES AND PUBLICATION. The Licensee must obtain written consent from the Licensor before the Licensee use the names, trademarks or logos of the Licensor.
USE OF NAMES AND PUBLICATION. The Visitor and the Visitor’s Institution must: obtain written consent from the Director/Head before: including any of the University’s Confidential Information in a publication; using the name of The University of Adelaide or any trade xxxx or logo of the University; or making a public statement about this Agreement; and give due acknowledgment to the University and its Personnel in any publication that draws upon the Results. Where an academic publication is as a result of joint authorship, both Parties must approve the publication. Such approval must not be unreasonably withheld. A Party may request delay to the publication to protect its Intellectual Property or the removal of its Confidential Information. Unless otherwise agreed, copyright in joint academic publications shall vest jointly in the University and the Visitor’s Institution.
USE OF NAMES AND PUBLICATION. Nothing contained in this Agreement shall be construed as granting any right to the Licensee or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of Licensor or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of Licensor in each case. Nothing herein shall be deemed to establish a relationship of principal and agent between Licensor and the Licensee, nor any of their agents or employees for any purpose whatsoever.
USE OF NAMES AND PUBLICATION. Nothing contained in this Agreement shall be construed as granting any right to any party to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of any other party or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior written consent of such party; provided, however, that each of the parties hereto acknowledges and agrees that IDDS may use the name of such party in various documents used by IDDS for capital raising and financing without such prior written consent where the use of such names may be required by law.
USE OF NAMES AND PUBLICATION. 16.01 Nothing contained in this Agreement shall be construed as granting any right to OXIQUANT or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of OHSU or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of OHSU, provided, however, that OHSU acknowledge and agree that OXIQUANT may use the names of OHSU and the names of the Principal Investigators in various documents used by OXIQUANT for capital raising and financing without such prior written consent where the use of such names is required by law and in any such event OXIQUANT shall use reasonable efforts to notify OHSU and the Principal Investigator of any such use prior to the use or, if prior notification is not possible, promptly thereafter. OHSU acknowledge that the Principal Investigators may act as consultants and scientific advisors to OXIQUANT with respect to the licenses granted to OXIQUANT hereunder, subject to the respective policies of OHSU.
16.02 Nothing herein shall be deemed to establish a relationship of principal and agent between OHSU and OXIQUANT, nor any of their agents or employees for any purpose whatsoever. This Agreement shall not be construed as creating a partnership between OHSU and OXIQUANT, or as creating any other form of legal association or arrangement which would impose liability upon one party for the act or failure to act of the other party.
16.03 In the event that OHSU or Principal Investigators desire, individually or as a group, to publish or disclose, by written, oral or other presentation, Know-how, Licensed Patent Rights, or any material information related thereto then OHSU or the Principal Investigator(s) shall notify OXIQUANT and in writing by facsimile where confirmed by the receiving party, and/or by certified or registered mail (return receipt requested) of their intention at least sixty (60) days prior to any speech, lecture or other oral presentation and at least sixty (60) days before any written or other publication or disclosure, The Principal Investigator(s) shall include with such notice a description of any proposed oral presentation or, in any proposed written or other disclosure, a current draft of such proposed disclosure or abstract. OXIQUANT may request that the Principal Investigator(s) and OHSU, no later than thirty (30) days following the receipt of such notice, delay such pres...
USE OF NAMES AND PUBLICATION. (a) The Licensee must obtain written consent from the Licensor before it:
(i) uses the names, trademarks or logos of the Licensor; or
(ii) makes a public statement about this Agreement.
USE OF NAMES AND PUBLICATION. 14.1 Nothing contained in this Agreement shall be construed as granting any right to the Company or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of the Licensor or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of the Licensor; provided, however, that the Licensor acknowledges and agrees that the Company may use the name of the Licensor and the names of the Principal Investigators in various documents used by the Company for capital raising and financing without such prior written consent but only to the extent that such use of names may be reasonably required by law. The Licensor acknowledges that the Principal Investigators may act as consultants and scientific advisors to the Company with respect to the licenses granted to the Company hereunder, subject to the respective policies of the Licensor.
14.2 Nothing herein shall be deemed to establish a relationship of principal and agent between the Licensor and the Company, nor any of their agents or employees for any purpose
